Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To directly assess the role of loss of E-cadherin in prostate tumor progression, we generated a new mouse model with bigenic Cdh1 and Pten deletion in prostate epithelium.
|
31658259 |
2019 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
|
29295717 |
2018 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.
|
22581815 |
2012 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The E-cadherin (CDH1)--160 C/A polymorphism and prostate cancer risk: a meta-analysis.
|
18781193 |
2009 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Beta-catenin mediates alteration in cell proliferation, motility and invasion of prostate cancer cells by differential expression of E-cadherin and protein kinase D1.
|
17979146 |
2008 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone.
|
18008331 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate cancer patients.
|
18618693 |
2008 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.
|
18459457 |
2007 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Significance of an E-cadherin gene promoter polymorphism for risk and disease severity of prostate cancer in a Japanese population.
|
17656222 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men.
|
16813949 |
2006 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
E-cadherin polymorphisms and haplotypes influence risk for prostate cancer.
|
16372334 |
2006 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
|
16301117 |
2006 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP.
|
16189707 |
2005 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer.
|
16226102 |
2005 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
E-cadherin gene 3'-UTR C/T polymorphism is associated with prostate cancer.
|
16327305 |
2005 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
|
16172196 |
2005 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells.
|
14511406 |
2004 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Dual roles of E-cadherin in prostate cancer invasion.
|
14991757 |
2004 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
-160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer.
|
14961571 |
2004 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells.
|
12393869 |
2003 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer.
|
14695147 |
2003 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer.
|
12209606 |
2002 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Association of E-cadherin germ-line alterations with prostate cancer.
|
11705864 |
2001 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
However, no specific deletion map has been constructed from prostate tumors to determine whether CDH1 is the potential target gene for the observed LOH on 16q.
|
9067271 |
1997 |